回复wmmsx发表于:2016/5/15 16:03:35悬赏金额:
50积分 状态:
未解决
【序号】:1
【作者】:Toguchi H1, Ogawa Y, Okada H, Yamamoto M.
【题名】:.
【期刊】:Yakugaku Zasshi.
【年、卷、期、起止页码】:1991 Aug;111(8):397-409.
【全文链接】:https://www.ncbi.nlm.nih.gov/pubmed/1795229
【序号】:2
【作者】:Ogawa Y, Okada H, Yamamoto M, Shimamoto T.
【题名】:In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers.
【期刊】:Chem Pharm Bull (Tokyo).
【年、卷、期、起止页码】:1988 Jul;36(7):2576-81.
【全文链接】:https://www.ncbi.nlm.nih.gov/pubmed/3149211
【序号】:3
【作者】:Asano M1, Fukuzaki H, Yoshida M, Kumakura M, Mashimo T, Yuasa H, Imai K, Yamanaka H.
【题名】:In vivo characteristics of low molecular weight copoly (D,L-lactic acid) formulations with controlled release of LH-RH agonist.
【期刊】:Biomaterials.
【年、卷、期、起止页码】:1989 Oct;10(8):569-73.
【全文链接】:https://www.ncbi.nlm.nih.gov/pubmed/2513891
【序号】:4
【作者】:Takada S1, Ogawa Y.
【题名】:.
【期刊】:Nihon Rinsho.
【年、卷、期、起止页码】:1998 Mar;56(3):675-9.
【全文链接】:https://www.ncbi.nlm.nih.gov/pubmed/9549355
【序号】:5
【作者】:Toguchi H1.
【题名】:Formulation study of leuprorelin acetate to improve clinical performance.
【期刊】:Clin Ther.
【年、卷、期、起止页码】:1992;14 Suppl A:121-30.
【全文链接】:https://www.ncbi.nlm.nih.gov/pubmed/1606592